lactobacillus paracasei NTU 101

Lactobacillus paracasei NTU 101 is a specific probiotic strain originally isolated from the intestines of healthy, breast-fed infants. [1, 5] It was developed by Professor Tzu-Ming Pan's research team at National Taiwan University, and the technology was exclusively authorized to SunWay Biotech Co., Ltd. for commercialization. [1, 9] The strain is marketed under the brand name Vigiis 101-LAB. [1] It has received Generally Recognized As Safe (GRAS) status from the U.S. FDA (GRN 001232). [4] Numerous studies have demonstrated its high tolerance to gastric acid and bile salts, allowing it to survive passage through the gastrointestinal tract. [1, 5] Its proposed mechanisms of action include modulating the gut microbiota, enhancing gut barrier function, and regulating the immune system. [3, 8, 10] Specifically, it has been shown to increase beneficial bacteria like Bifidobacterium and Lactobacillus, improve intestinal peristalsis, and balance the T-helper (Th1/Th2) cell response. [2, 4, 14] Clinical and preclinical studies suggest benefits for digestive health, atopic dermatitis, immune support, and managing metabolic conditions like obesity and high cholesterol. [2, 3, 6, 10]

Brand names

Vigiis 101-LABVigiis101-LABVigiis-101-LAB

Other names

Lacticaseibacillus paracasei subsp. paracasei NTU 101Lactobacillus paracasei subsp. paracasei NTU 101